Targeted next-generation sequencing–based mutational signature analysis in endometrial cancer: utility and limitations across molecular subtypes
Background: Molecular subtype classification is essential for staging endometrial cancer, planning adjuvant treatments, and stratifying prognosis. However, the correlation between mutational signature analysis using tumor-only targeted next-generation sequencing (NGS) data and molecular subtypes, as well as the interpretive value at the individual case level, remains inadequately characterized. Methods: We performed mutational signature analysis on tumor-only targeted NGS data from 72 endometrial cancer cases using the SATS R package. Molecular classification into four subtypes (POLE-mutated, mismatch repair deficient [MMRd], TP53-mutant, and no specific molecular profile [NSMP]) was established through a standard stepwise algorithm that integrated NGS and immunohistochemistry. Results: Out of the 72 endometrial cancers, 12 were classified as POLE-mutated, 10 as MMRd, six as TP53-mutant, and 44 as NSMP. All POLE-mutated tumors exhibited POLE-associated signatures (SBS10a/SBS10b), including cases with non-hotspot POLE exonuclease variants and tumor mutation burdens below the conventional ultramutation threshold. MMRd-associated signatures showed a broader distribution across molecular subtypes; while the summed MMRd-associated signatures were typically higher in MMRd tumors, low-level contributions were also noted in subsets of NSMP and TP53-mutant tumors. Within the POLE-mutated group, MMRd-associated signatures were more pronounced in cases displaying subclonal MMR protein loss as determined by immunohistochemistry. Conclusions: In this small, clinically selected cohort, targeted NGS-based mutational signatures provided exploratory, complementary information regarding POLE-associated mutagenesis and mixed MMR-related patterns. Overlapping signature distributions, dependence on the analytical pipeline, and the use of tumor-only targeted sequencing limit case-level interpretation. Mutational signature analysis should be interpreted in conjunction with established molecular tests and should not be used as a stand-alone classifier.
Authors
- Sung Jong Lee (ORCID: https://orcid.org/0000-0002-6077-2649)
- Sook Hee Hong (ORCID: https://orcid.org/0000-0003-4299-5694)
- Keun Ho Lee (ORCID: https://orcid.org/0000-0001-9005-7796)
- Sungyoung Lee (ORCID: https://orcid.org/0000-0003-3458-1440)
- Jun Kyu Kang (ORCID: https://orcid.org/0000-0002-7967-0917)
- Donghyuk Lee (ORCID: https://orcid.org/0009-0005-8348-6564)
- Miseon Lee (ORCID: https://orcid.org/0000-0002-6385-7621)
- Uijin Kim (ORCID: https://orcid.org/0009-0003-6492-8289)
Institutions
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Pusan National University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Journal of Pathology and Translational Medicine
- Published
- 2026-11-12
- DOI
- https://doi.org/10.4132/jptm.2026.09.07
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00